I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Les Korsh Biography and Net Worth

VP of iTeos Therapeutics

Les Korsh is the VP of iTeos Therapeutics.

What is Les B. Korsh's net worth?: The estimated net worth of Les B. Korsh is at least $769,936.30 as of July 3rd, 2024. Korsh owns 103,765 shares of iTeos Therapeutics stock worth more than $769,936 as of December 21st. This net worth approximation does not reflect any other assets that Korsh may own. Learn More about Les B. Korsh's net worth.
How do I contact Les B. Korsh?: The corporate mailing address for Korsh and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Les B. Korsh's contact information.
Has Les B. Korsh been buying or selling shares of iTeos Therapeutics?: Les B. Korsh has not been actively trading shares of iTeos Therapeutics during the last ninety days. Learn More on Les B. Korsh's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $38,650.00. The most recent insider tranaction occured on November, 19th when CFO Matthew Gall bought 5,000 shares worth more than $38,650.00. Insiders at iTeos Therapeutics own 12.5% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 11/19/2024.

Les B. Korsh Insider Trading History at iTeos Therapeutics

Les B. Korsh Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $7.42

$7.09

$7.51

50 Day Range

MA: $8.54

$7.22

$9.73

2 Week Range

Now: $7.42

$7.09

$18.75

Volume

2,443,768 shs

Average Volume

452,593 shs

Market Capitalization

$271.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

I was wrong. Dead wrong.

From Porter & Company | Ad